Literature DB >> 12235180

Identification of Egr1 as the oncostatin M-induced transcription activator that binds to sterol-independent regulatory element of human LDL receptor promoter.

Fang Zhang1, Thomas E Ahlborn, Cong Li, Fredric B Kraemer, Jingwen Liu.   

Abstract

Previously, we identified the low density lipoprotein receptor (LDLR) promoter region -17 to -1 as a novel sterol-independent regulatory element (SIRE) that mediates the stimulating effect of oncostatin M (OM). The goal of this study was to identify the OM-induced transcription activator that binds to the SIRE sequence. By conducting a electrophoretic mobility shift assay (EMSA) followed by UV crosslinking and SDS-PAGE, we show that a protein with a molecular mass of 85 kDa was present in the OM-induced SIRE DNA-protein complex. Western blotting and supershift assays reveal that the 85 kDa factor is early growth response gene 1 (Egr1). The interaction of Egr1 with the SIRE sequence was further confirmed in vivo by chromatin immunoprecipitation assays. The functional role of Egr1 in LDLR transcription was assessed by cotransfection of an Egr1 expression vector with an LDLR promoter reporter construct. We show that overexpression of Egr1 significantly increases LDLR promoter activity when cotransfected with CCAAT/enhancer binding protein beta (c/EBPbeta) or with cAMP-responsive element binding protein (CREB) expression vectors. Our studies clearly demonstrate that Egr1 is the OM-induced transcription factor that binds to the SIRE sequence of the LDLR promoter and also suggest that Egr1 may have a functional role in OM-induced upregulation of LDLR transcription through interaction with other SIRE binding proteins such as c/EBPbeta or CREB.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12235180     DOI: 10.1194/jlr.m200126-jlr200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  8 in total

1.  Blockage of oncostatin M-induced LDL receptor gene transcription by a dominant-negative mutant of C/EBPbeta.

Authors:  Yue Zhou; Fang Zhang; Parveen Abidi; Meihong Lin; Gerald Thiel; Jingwen Liu
Journal:  Biochem J       Date:  2006-07-01       Impact factor: 3.857

2.  Identification of heterogeneous nuclear ribonucleoprotein K as a transactivator for human low density lipoprotein receptor gene transcription.

Authors:  Hai Li; Jingwen Liu
Journal:  J Biol Chem       Date:  2010-04-06       Impact factor: 5.157

3.  Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells.

Authors:  Aiqin Cao; Minhao Wu; Hai Li; Jingwen Liu
Journal:  J Lipid Res       Date:  2010-12-31       Impact factor: 5.922

4.  Early growth response 1 (Egr1) regulates cholesterol biosynthetic gene expression.

Authors:  Nolan G Gokey; Camila Lopez-Anido; Anne Lynn Gillian-Daniel; John Svaren
Journal:  J Biol Chem       Date:  2011-06-28       Impact factor: 5.157

5.  Modified methylenedioxyphenol analogs lower LDL cholesterol through induction of LDL receptor expression.

Authors:  Zhekang Ying; Rajagopal Desikan; Xiaohua Xu; Andrei Maiseyeu; Cuiqing Liu; Qinghua Sun; Ouiliana Ziouzenkova; Sampath Parthasarathy; Sanjay Rajagopalan
Journal:  J Lipid Res       Date:  2012-02-21       Impact factor: 5.922

6.  Modulators of hepatic lipoprotein metabolism identified in a search for small-molecule inducers of tribbles pseudokinase 1 expression.

Authors:  Marek M Nagiec; Adam P Skepner; Joseph Negri; Michelle Eichhorn; Nicolas Kuperwasser; Eamon Comer; Giovanni Muncipinto; Aravind Subramanian; Clary Clish; Kiran Musunuru; Jeremy R Duvall; Michael Foley; Jose R Perez; Michelle A J Palmer
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

7.  Therapeutic targets of hypercholesterolemia: HMGCR and LDLR.

Authors:  Shizhan Ma; Wenxiu Sun; Ling Gao; Shudong Liu
Journal:  Diabetes Metab Syndr Obes       Date:  2019-08-21       Impact factor: 3.168

8.  Role of early growth response 1 in liver metabolism and liver cancer.

Authors:  Nancy Magee; Yuxia Zhang
Journal:  Hepatoma Res       Date:  2017-11-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.